ADMA BIOLOGICS, INC. Contract Liability (Deferred Revenue)
ADMA BIOLOGICS, INC. (ADMA) had Contract Liability (Deferred Revenue) of $143.00 thousand as of 2025-06-30, per its 10-Q filed 2025-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2025-08-06
- 2025-06-30: Contract with Customer, Liability, Current $143.00K.
- 2025-03-31: Contract with Customer, Liability, Current $143.00K.
- 2024-12-31: Contract with Customer, Liability, Current $143.00K.
- 2024-09-30: Contract with Customer, Liability, Current $143.00K.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2025-06-30 | $143.00K 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $143.00K 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $143.00K 10-Q · filed 2025-08-06 | |
| 2024-09-30 | $143.00K 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $1.13M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $1.12M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $182.00K 10-K · filed 2025-03-18 | |
| 2023-09-30 | $142.83K 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $142.83K 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $142.83K 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $143.00K 10-K · filed 2024-02-28 | $142.83K 10-K · filed 2023-03-23 |
| 2022-09-30 | $142.83K 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $142.83K 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $142.83K 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $142.83K 10-K · filed 2023-03-23 | |
| 2021-09-30 | $142.83K 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $142.83K 10-Q · filed 2021-08-11 | |
| 2020-12-31 | $142.83K 10-K · filed 2022-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |